Pharma BD Deal Intelligence

Hebei Senlang Biotechnology Co., Ltd. / Tempest Therapeutics, Inc.

2026 · Co-Development · Complete

Tempest Therapeutics and Hebei Senlang Biotechnology entered a development collaboration under which Senlang will run a first-in-human investigator-initiated trial of TPST-4003 in approximately 10 patients with autoimmune neurological disease in China, with first patient dosing expected in Q4 2026. TPST-4003 pairs Tempest's CD7-targeted mRNA/LNP delivery platform with a CD19/BCMA dual-target CAR construct; Senlang holds an option to negotiate an exclusive China license and headline financial terms were not disclosed in the announcement.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals